Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP Oxaliplatin + mFOLFIRI for Peritoneal Carcinomatosis
NCT04158349Phase 1Terminated
- Sponsor
- University of Utah
- Start
- Mar 2021
- Primary completion
- May 2021
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 1, open-label trial of oxaliplatin in colorectal cancer (CRC), appendiceal cancer and peritoneal carcinomatosis (PC) (3 arms), sponsored by University of Utah. Primary endpoint: Maximum Tolerated Dose at 42 days. Started Mar 2021; status: terminated.
02
Drugs
oxaliplatin
03
Conditions
colorectal cancer (CRC)appendiceal cancerperitoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT04158349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04158349.